# NCT02950766 (NeoVax): what clinicians are saying

> 115 statements from 24 sources (3 videos, 20 posts, 1 paper), 40 of them from 13 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
- NCT ID: NCT02950766
- Registry: https://clinicaltrials.gov/study/NCT02950766
- Sponsor: Patrick Ott, MD, PhD
- Phase: Phase 1
- Status: Active, not recruiting
- Drugs tested: NeoVax plus ipilimumab; NeoVax
- Indication: high-risk renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 23d7f463b670502a7f89d581f67590cdb10bcc03879d56b1e64c475fdf153b14

## Counts

- Commentary sources screened: 37
- Sources cited by verified statements: 24
- Verified statements: 115
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 40
- Findings: 9
- Named people in screened sources (unnamed speakers and accounts not counted): 22
- Speakers cited: 22
- Cited speakers with a verified identity: 15
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 13
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 13
- By role and specialty (the abstract's specialty counts):
  - 7 physician, Medical oncology
  - 4 physician, specialty not confirmed
  - 1 physician, Cardiology
  - 1 physician, Radiation oncology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited see NCT02950766 as support for pursuing personalized vaccination, pointing to tumor-directed immune responses, but a medical oncologist interprets the findings more definitively as showing clinical benefit. Another medical oncologist judges tolerability favorably, alongside a relayed patient experience describing treatment as difficult at times. Comparative benefit and uncommon harms remain beyond what the sources reviewed for this edition can establish.

## Findings (titles)

- F1. Adjuvant RCC vaccine: most speakers welcome it, and most highlight efficacy
  - 11 statements from 7 speakers in 9 sources.
  - 6 of the 7 named speakers in this finding hold this view; 5 of the 7 hold its caveat, “most highlight efficacy”.
  - 5 of the report's 13 cited clinicians.
- F2. RCC vaccines: how most clinicians distinguish neoantigen targeting from older approaches
  - 13 statements from 3 speakers in 5 sources, 2 of them podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician.
  - 3 of the report's 13 cited clinicians.
- F3. Adjuvant RCC vaccination: what clinicians highlight about the toxicity burden
  - 7 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician.
  - 2 of the report's 13 cited clinicians.
- F4. RCC protein vaccines: clinicians see feasibility but one flags complexity
  - 6 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags complexity”.
  - 2 of the report's 13 cited clinicians.
- F5. RCC vaccine research: why most speakers fear political and funding threats
  - 7 statements from 5 speakers in 1 source.
  - 4 of the 5 named speakers in this finding hold this view.
  - No named clinician · accounts and unnamed speakers.
- F9. RCC vaccines: a speaker favors affordability, offers trial help if wanted
  - 4 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “offer trial help if wanted”.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F6. RCC vaccines: why clinicians look to randomized testing with adjuvant pembrolizumab
  - 7 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician.
  - 2 of the report's 13 cited clinicians.
- F7. RCC vaccination after surgery: what speakers say
  - 5 statements from 1 speaker in 2 sources, 1 of them a podcast or video.
  - 1 of the report's 13 cited clinicians.
- F8. Non-clear-cell RCC: why a speaker flags uncertainty about vaccine-trial inclusion
  - 2 statements in 2 sources.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

3 of the 9 findings and 12 of the 115 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 12 | 9 | 7 | 3 |
| F2 | 13 | 9 | 5 | 3 | 3 |
| F3 | 7 | 5 | 4 | 2 | 3 |
| F4 | 6 | 4 | 3 | 2 | 2 |
| F5 | 7 | 9 | 1 | 5 | 3 |
| F9 | 4 | 6 | 1 | 1 | 3 |
| F6 | 7 | 4 | 3 | 2 | 3 |
| F7 | 5 | 3 | 2 | 1 | 3 |
| F8 | 2 | 2 | 2 | 0 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 1 | 0 | 0 | 3 | 14 | 1 | 8 posts and articles, 1 publication |
| F2 | 7 | 0 | 0 | 4 | 2 | 15 | 0 | 2 posts and articles, 2 podcasts and video, 1 publication |
| F3 | 4 | 0 | 0 | 1 | 2 | 7 | 0 | 2 posts and articles, 1 podcast or video, 1 publication |
| F4 | 0 | 0 | 2 | 0 | 4 | 6 | 0 | 1 post or article, 1 podcast or video, 1 publication |
| F5 | 7 | 0 | 0 | 0 | 0 | 8 | 1 | 1 post or article |
| F9 | 3 | 0 | 0 | 1 | 0 | 4 | 2 | 1 post or article |
| F6 | 4 | 0 | 1 | 1 | 1 | 8 | 0 | 1 post or article, 1 podcast or video, 1 publication |
| F7 | 0 | 0 | 1 | 0 | 4 | 7 | 0 | 1 post or article, 1 podcast or video |
| F8 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 1 post or article, 1 publication |

### Trial dimensions

- Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0: no finding draws on it directly
- Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (2 shared claims)
- Secondary endpoint: Number of participants alive at 2 years: no finding draws on it directly
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims)
- The comparison: F2 (3 shared claims), F4 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (1 shared claims)
- Design and conduct: F2 (2 shared claims), F4 (1 shared claims)

## Abbreviations

- DLT: dose-limiting toxicity
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- RCC: renal cell carcinoma

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 115 | Paid |
| Who said each statement: the cited speakers | 22 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 13 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 15 | Free |
| Sources with links | 24 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 13 of the 22 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

13 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0 | no commentary found | 0 | 0 |
| Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16 | discussed | 12 | 10 |
| Secondary endpoint: Number of participants alive at 2 years | no commentary found | 0 | 0 |
| Population and setting | discussed | 12 | 6 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 5 |
| Safety and tolerability | discussed | 6 | 5 |
| Design and conduct | discussed | 11 | 7 |
| How clinical authors and accounts interpret adjuvant promise | discussed | 30 | 21 |
| Why speakers distinguish neoantigen selection from earlier RCC vaccines | discussed | 5 | 3 |
| How speakers explain tumor-directed immune activity | discussed | 16 | 5 |
| How accounts weigh personalized manufacture and alternative platforms | discussed | 8 | 4 |
| How speakers frame randomized add-on development and sequencing | discussed | 9 | 6 |
| How accounts discuss affordability, navigation and patient support | discussed | 7 | 2 |
| How accounts connect vaccine promise with research-funding concerns | discussed | 8 | 1 |
| How accounts frame therapeutic vaccination and cross-cancer extrapolation | discussed | 10 | 3 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 19 statements · 17%** | | | |
| YouTube | 19 | 3 | 3 |
| **Posts · 68 statements · 59%** | | | |
| X threads | 34 | 14 | 26 |
| Bluesky threads | 34 | 6 | 8 |
| **Primary sources · 28 statements · 24%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 28 | 1 | not screened |

- Screened window: 2019-03-09 to 2026-11-09
- Cited window: 2021-08-25 to 2026-08-11
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
- Registry: NCT02950766 (https://clinicaltrials.gov/study/NCT02950766)
- Study IDs: 16-097
- Sponsor: Patrick Ott, MD, PhD
- Collaborators: Bristol-Myers Squibb, Oncovir, Inc.
- Design: Phase 1 · interventional, non randomized, single group, phase1
- Status: Active, not recruiting
- Enrollment: 19 (estimated)
- Start: 2019-03-03 (actual)
- Primary completion: 2027-12-31 (estimated)
- Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0 (49 days)
- Intervention: NeoVax (drug)
- Intervention: Ipilimumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 34 sources about other trials or topics are not included; 2 sources that may describe the trial without naming it were not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The central published experience is small and nonrandomized. It cannot establish comparative efficacy or reliably characterize uncommon harms; the higher local-ipilimumab-dose cohort was not part of the reported analysis.
- The sources reviewed are not a representative sample of HCP practice. Reposts and cross-platform repeats do not add independent judgments, and source-described trial contributors are not external validation.
- Clinical roles are not established for several named social accounts, and unidentified spoken passages cannot be assigned to a person from a programme title, description or participant list.
- No separate protocol or NeoVax-specific regulatory label was available in the sources reviewed. This report does not establish regulatory status, reimbursement or routine access.
- Follow-up study descriptions retain their own publication dates and accrual wording. Without a verified shared study identifier, they should not be treated as a single timeline, a change of mind or follow-up efficacy evidence.
- Cross-cancer mRNA comparisons, non-clear-cell applicability, comparative production costs and individual trial eligibility remain unresolved in these sources.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 115 verified statements · 40 from 13 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (15 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/nct02950766
- Agents: POST https://www.erudio.com/api/orders with {"report": "nct02950766", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=nct02950766

## Cite

Erudio Health. NCT02950766 (NCT02950766): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/nct02950766

## Questions

### How much does the NCT02950766 report cost?

One edition costs $750 (Focused · 115 verified statements · 40 from 13 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the NCT02950766 report cover?

115 statements from 24 sources (3 videos, 20 posts, 1 paper), 40 of them from 13 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the NCT02950766 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "nct02950766" }) previews it and create_order({ "report": "nct02950766", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the NCT02950766 report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/nct02950766.json
- Markdown: https://www.erudio.com/reports/nct02950766.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/nct02950766/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "nct02950766"}`
